Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis

Clinical and Vaccine Immunology

Volumn 18, Issue 8, 2011, Pages 1252-1260

  Mak, Puiying A ^a   Santos, George F ^b   Masterman, Kelly Anne ^a   Janes, Jeff ^a   Wacknov, Bill ^a   Vienken, Kay ^c   Giuliani, Marzia ^c   Herman, Ann E ^a   Cooke, Michael ^a   Mbow, M Lamine ^b   Donnelly, John ^b  

^a GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^b Novartis Vaccines and Diagnostics Inc   (United States)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; COMPLEMENT; RESAZURIN;

ADULT; ANTIBODY TITER; ARTICLE; AUTOANALYSIS; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CELL RESPIRATION; CONTROLLED STUDY; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT SERUM BACTERICIDAL ASSAY; HUMAN; INTERMETHOD COMPARISON; MICROBIAL RESPIRATION; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REPRODUCIBILITY; SERUM BACTERICIDAL ANTIBODY ASSAY;

ANTIBODIES, BACTERIAL; AUTOMATION; BLOOD BACTERICIDAL ACTIVITY; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOASSAY; MENINGOCOCCAL VACCINES; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS; OXAZINES; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; XANTHENES;

EID: 79961111441     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05028-11     Document Type: Article

References (17)

1. Borrow, R., et al. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab Immunol. 12:970-976.
2. Borrow, R., et al. 2006. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093-5107. (Pubitemid 44209069)
3. Campbell, H., R. Borrow, D. Salisbury, and E. Miller. 2009. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27:B20-B29.
4. Gill, C. J., R. Baxter, A. Anemona, G. Ciavarro, and P. Dull. 2010. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo(R)) or Menactra(R) among healthy adolescents. Hum. Vaccin. 6:881-887.
5. Giuliani, M. M., et al. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28:5023-5030.
6. Goegan, P., G. Johnson, and R. Vincent. 1995. Effects of serum protein and colloid on the alamarBlue assay in cell cultures. Toxicol. In Vitro 9:257-266.
7. Goldschneider, I., E. C. Gotschlich, and M. S. Artenstein. 1969. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1307-1326.
8. Granoff, D. M., J. A. Welsch, and S. Ram. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769.
9. Holst, J., et al. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21:734-737. (Pubitemid 36091989)
10. Lennon, D., et al. 2009. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin. Infect. Dis. 49:597-605.
11. Michael, S., et al. 2008. A robotic platform for quantitative high-throughput screening. Assay Drug Dev. Technol. 6:637-657.
12. Milagres, L. G., et al. 1994. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
13. Mountzouros, K. T., and A. P. Howell. 2000. Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis. J. Clin. Microbiol. 38:2878-2884. (Pubitemid 30640566)
14. Rodríguez, T., et al. 2003. Validation of colorimetric assay to detect complement- mediated antibody-dependent bactericidal activity against serogroups B and C Neisseria meningitidis. Biologicals 31:209-212. (Pubitemid 36993717)
15. Romero-Steiner, S., et al. 2004. Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin. Diagn. Lab. Immunol. 11:89-93. (Pubitemid 38090657)
16. Sierra, G. V., et al. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-210.
17. Toneatto, D., et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum. Vaccin., in press.